230 related articles for article (PubMed ID: 19546225)
1. Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS.
Vitour D; Dabo S; Ahmadi Pour M; Vilasco M; Vidalain PO; Jacob Y; Mezel-Lemoine M; Paz S; Arguello M; Lin R; Tangy F; Hiscott J; Meurs EF
J Biol Chem; 2009 Aug; 284(33):21797-21809. PubMed ID: 19546225
[TBL] [Abstract][Full Text] [Related]
2. Regulation of I(kappa)B kinase complex by phosphorylation of (gamma)-binding domain of I(kappa)B kinase (beta) by Polo-like kinase 1.
Higashimoto T; Chan N; Lee YK; Zandi E
J Biol Chem; 2008 Dec; 283(51):35354-67. PubMed ID: 18957422
[TBL] [Abstract][Full Text] [Related]
3. The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1.
Zhang W; Wang J; Zhang Y; Yuan Y; Guan W; Jin C; Chen H; Wang X; Yang X; He F
Mol Biol Cell; 2010 Jul; 21(14):2500-13. PubMed ID: 20484576
[TBL] [Abstract][Full Text] [Related]
4. Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP).
Johnson TM; Antrobus R; Johnson LN
Biochemistry; 2008 Mar; 47(12):3688-96. PubMed ID: 18298087
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B
Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
[TBL] [Abstract][Full Text] [Related]
7. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
8. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting.
Hanisch A; Wehner A; Nigg EA; Silljé HH
Mol Biol Cell; 2006 Jan; 17(1):448-59. PubMed ID: 16267267
[TBL] [Abstract][Full Text] [Related]
9. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
10. DDX3 directly regulates TRAF3 ubiquitination and acts as a scaffold to co-ordinate assembly of signalling complexes downstream from MAVS.
Gu L; Fullam A; McCormack N; Höhn Y; Schröder M
Biochem J; 2017 Feb; 474(4):571-587. PubMed ID: 27980081
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
12. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks.
Mao XL; Wang KF; Zhu F; Pan ZH; Wu GM; Zhu HY
Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535
[TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling of the TRAF3 interactome network reveals a new role for the ER-to-Golgi transport compartments in innate immunity.
van Zuylen WJ; Doyon P; Clément JF; Khan KA; D'Ambrosio LM; Dô F; St-Amant-Verret M; Wissanji T; Emery G; Gingras AC; Meloche S; Servant MJ
PLoS Pathog; 2012; 8(7):e1002747. PubMed ID: 22792062
[TBL] [Abstract][Full Text] [Related]
14. WAC Promotes Polo-like Kinase 1 Activation for Timely Mitotic Entry.
Qi F; Chen Q; Chen H; Yan H; Chen B; Xiang X; Liang C; Yi Q; Zhang M; Cheng H; Zhang Z; Huang J; Wang F
Cell Rep; 2018 Jul; 24(3):546-556. PubMed ID: 30021153
[TBL] [Abstract][Full Text] [Related]
15. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
16. TRAF5 is a downstream target of MAVS in antiviral innate immune signaling.
Tang ED; Wang CY
PLoS One; 2010 Feb; 5(2):e9172. PubMed ID: 20161788
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions.
Bibi N; Parveen Z; Rashid S
PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA.
Niiya F; Tatsumoto T; Lee KS; Miki T
Oncogene; 2006 Feb; 25(6):827-37. PubMed ID: 16247472
[TBL] [Abstract][Full Text] [Related]
19. A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response.
Paz S; Vilasco M; Werden SJ; Arguello M; Joseph-Pillai D; Zhao T; Nguyen TL; Sun Q; Meurs EF; Lin R; Hiscott J
Cell Res; 2011 Jun; 21(6):895-910. PubMed ID: 21200404
[TBL] [Abstract][Full Text] [Related]
20. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate.
Lowery DM; Clauser KR; Hjerrild M; Lim D; Alexander J; Kishi K; Ong SE; Gammeltoft S; Carr SA; Yaffe MB
EMBO J; 2007 May; 26(9):2262-73. PubMed ID: 17446864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
